Cargando…

New developments in the management of severe skin and deep skin structure infections – focus on tedizolid

Tedizolid, a novel oxazolidinone, is approved for treatment of acute bacterial skin and skin structure infections (ABSSSIs). Tedizolid offers several potential advantages over current ABSSSI treatment options. First, tedizolid has a prolonged half-life, which allows for once-daily dosing. Second, te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durkin, Michael J, Corey, G Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447168/ https://www.ncbi.nlm.nih.gov/pubmed/26045667 http://dx.doi.org/10.2147/TCRM.S64553

Ejemplares similares

Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections
por: Ferrández, Olivia, et al.
Publicado: (2016)

Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections
por: Hall, Ronald G, et al.
Publicado: (2015)

Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections
por: Urbina, Olatz, et al.
Publicado: (2013)

Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA
por: McCool, Rachael, et al.
Publicado: (2017)

Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy
por: Bassetti, Matteo, et al.
Publicado: (2019)

Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis
por: Lan, Shao-Huan, et al.
Publicado: (2019)

471. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate (TZD) in Adolescents with Acute Bacterial Skin and Skin Structure Tissue Infections (ABSSSI)
por: Bradley, John S, et al.
Publicado: (2019)

Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections
por: Li, Dan, et al.
Publicado: (2021)

Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections
por: Ortiz-Covarrubias, Alejandro, et al.
Publicado: (2016)

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection
por: Lv, Xiaoju, et al.
Publicado: (2019)

Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials
por: Moran, Gregory J., et al.
Publicado: (2018)

Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting
por: Kullar, Ravina, et al.
Publicado: (2020)

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Corey, G Ralph, et al.
Publicado: (2019)

In Vitro Activity of Tedizolid Against Gram-Positive Bacteria in Patients With Skin and Skin Structure Infections and Hospital-Acquired Pneumonia: A Korean Multicenter Study
por: Lee, Yangsoon, et al.
Publicado: (2015)

1547. Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials
por: De Anda, Carisa, et al.
Publicado: (2017)

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

262 Effect of NSAID/Corticosteroid Use on the Efficacy of Tedizolid in Acute Bacterial Skin and Skin Structure Infections: Pooled Data From the Phase 3 ESTABLISH-1 and ESTABLISH-2 Studies
por: Sandison, Taylor, et al.
Publicado: (2014)

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid
por: Vanegas Múnera, Johanna Marcela, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Tedizolid: new data and experiences for clinical practice
por: Lletí, Miguel Salavert, et al.
Publicado: (2021)

Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections
por: Wilcox, Mark H, et al.
Publicado: (2021)

Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection
por: Shaw, Timothy David, et al.
Publicado: (2021)

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections
por: Maraki, Sofia, et al.
Publicado: (2023)

Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin
por: Righi, Elda, et al.
Publicado: (2018)

In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid
por: Zhang, Huiyun, et al.
Publicado: (2022)

Development and Evaluation of Chitosan Nanoparticles for Ocular Delivery of Tedizolid Phosphate
por: Kalam, Mohd Abul, et al.
Publicado: (2022)

Safety and tolerability of tedizolid as oral treatment for bone and joint infections
por: Miller, Loren G., et al.
Publicado: (2023)

Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole
por: Barbour, April, et al.
Publicado: (2010)

Comparative Efficacy and Safety of Vancomycin, Linezolid, Tedizolid, and Daptomycin in Treating Patients with Suspected or Proven Complicated Skin and Soft Tissue Infections: An Updated Network Meta-Analysis
por: Feng, Jingjuan, et al.
Publicado: (2021)

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
por: Juul, Janelle J, et al.
Publicado: (2016)

Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
por: Jones, Travis M, et al.
Publicado: (2016)

306. Safety and Tolerability of Tedizolid as Oral Treatment for Bone and Joint Infections
por: Launer, Bryn, et al.
Publicado: (2018)

Tedizolid Phosphate: a Next-Generation Oxazolidinone
por: Rybak, Jeffrey M., et al.
Publicado: (2015)

Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline
por: Bidell, Monique R., et al.
Publicado: (2021)

Effect of the human endotoxin challenge on tedizolid tissue penetration
por: Jorda, Anselm, et al.
Publicado: (2022)

Moxifloxacin in the treatment of skin and skin structure infections
por: Guay, David RP
Publicado: (2006)

Ceftaroline in complicated skin and skin-structure infections
por: Hernandez, Paul O, et al.
Publicado: (2012)

1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Corey, Ralph, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_g34kt8uqgdtdofsb2d7v0e6c4b